Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier BV in Annals Of Oncology
- Vol. 5 (1), 37-42
- https://doi.org/10.1093/oxfordjournals.annonc.a058687
Abstract
Purpose: The purpose of the study was to assess the possible benefit of the combination vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced non- small cell lung cancer (NSCLC), not treated previously. It also involved confirmation of the efficacy of vinorelbine as monotherapy. Patients and methods: In this phase 111 trial, 231 eligible patients were stratified by centre and randomized to receive either NVB alone, 30 mg/m2/week or the combination of NVB 30 mg/m2/week and DDP 80 mg/m2/3 weeks. Patients were to be treated for a minimum of 6 weeks, with the first response assessment performed 9 weeks after the beginning of treatment. Results: The two groups differed in terms of objective response rates (16% and 43%, respectively, p = 0.0001) and median time to progression (10 weeks and 20 weeks, p = 0.0001). However, the difference was not significant for median survival time (32 weeks, 33 weeks, p = 0.48). The addition of DDP resulted in an increase in toxicity, in particular renal, hematologic, neurologic and emetic. This toxicity led to treatment discontinuation in 8% and 21% of patients, respectively. Respectively 3% and 13% of patients stopped treatment early during objective response (toxicity or refusal). Conclusions: The NVB-DDP combination increased objective response rates and time to progression in comparison with NVB alone, but did not influence the survival of patients. The activity of NVB in the treatment of advanced NSCLC was confirmed.This publication has 16 references indexed in Scilit:
- Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.Journal of Clinical Oncology, 1991
- A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinomaCancer, 1991
- A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1991
- Etoposideversus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: Results of a prospective randomized fonicap trialCancer, 1990
- A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.Journal of Clinical Oncology, 1986
- Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized studyEuropean Journal of Cancer and Clinical Oncology, 1984
- 5'-Nor anhydrovinblastineTetrahedron, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Planning the size and duration of a clinical trial studying the time to some critical eventJournal of Chronic Diseases, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958